Funding Details
- Awarder
- Inbox
- Date Award
- April 24, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Founding Year
- 2021
- Traction
- Endeavor BioMedicines revealed positive Phase 2 study results for ENV-101 in January, showing promise in improving lung function decline in idiopathic pulmonary fibrosis patients. They plan to conduct further studies with the new funding.
- Founders
- John Hood
- Company Description
- Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.
- Market
- Healthcare
- Location
-
San Diego,
California,
US
- Coinvestors
- AyurMaya, Matrix Capital Management
Links